Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 (SC) in Systemic Lupus Erythematosus
NCT06791772Phase 2Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in systemic lupus erythematosus (SLE), sponsored by Keymed Biosciences. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
cm313
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06791772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06791772.